SIRT3 and breast cancer: Accordingly, we aimed to investigate and explore the possible role of TUG-1/miR-186/SIRT3, PPAR-1α and HIF-1α axis in TMX resistance and TMX sensitive BC patients and to correlate the aforementioned axis with tumor progression, different clinical presentations, anthropometric parameters and other metabolic biomarkers in BC.